Inspire Medical Systems, Inc.
INSP Healthcare Medical Devices
Inspire Medical Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $912.0 million, up 13.6% from fiscal 2024. In the quarter to June 2026, revenue fell 7.60%, EPS grew 108.3% and free cash flow grew 322.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow INSP
Inspire Medical Systems, Inc. (INSP) EV/Sales
As of 16 October 2026, Inspire Medical Systems, Inc. (INSP) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from 1.0× (May 2026) to 54.5× (March 2021); the current reading is higher than 9% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.6× | (58.25%) |
| FY2024 | 6.3× | (21.74%) |
| FY2023 | 8.1× | (50.47%) |
| FY2022 | 16.3× | (37.25%) |
| FY2021 | 26.0× | (36.04%) |
| FY2020 | 40.7× | 103.36% |
| FY2019 | 20.0× | 123.59% |
| FY2018 | 8.9× | 681.62% |
| FY2017 | 1.1× | 0.00% |
| FY2016 | 1.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.1× | (17.66%) |
| Mar 2026 | 1.3× | (50.13%) |
| Dec 2025 | 2.6× | 25.16% |
| Sep 2025 | 2.1× | (48.60%) |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INSP Inspire Medical Systems, Inc. | 1.9× |
| NVCR NovoCure Limited compare | 2.0× |
| ATEC Alphatec Holdings, Inc. compare | 2.6× |
| NEOG Neogen Corporation compare | 3.6× |
| UFPT UFP Technologies, Inc. compare | 3.8× |
| TMDX TransMedics Group, Inc. compare | 4.2× |
| AXGN AxoGen, Inc. compare | 7.0× |
| ESTA Establishment Labs Holdings Inc. compare | 8.1× |
| BFLY Butterfly Network, Inc. compare | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)